Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.

Parmakhtiar B, Burger RA, Kim JH, Fruehauf JP.

Mol Cancer Res. 2019 Aug;17(8):1675-1686. doi: 10.1158/1541-7786.MCR-18-1109. Epub 2019 May 14.

PMID:
31088908
2.

Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma.

Fruehauf JP, El-Masry M, Osann K, Parmakhtiar B, Yamamoto M, Jakowatz JG.

Cancer Chemother Pharmacol. 2018 Aug;82(2):353-360. doi: 10.1007/s00280-018-3624-6. Epub 2018 Jun 25.

3.

Pharmacokinetics of single-agent axitinib across multiple solid tumor types.

Tortorici MA, Cohen EE, Pithavala YK, Garrett M, Ruiz-Garcia A, Kim S, Fruehauf JP.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1279-89. doi: 10.1007/s00280-014-2606-6. Epub 2014 Oct 22.

PMID:
25336084
4.

A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder.

Eroglu Z, Fruehauf JP.

Cancer Chemother Pharmacol. 2013 Jul;72(1):263-7. doi: 10.1007/s00280-013-2178-x. Epub 2013 May 1.

PMID:
23636451
5.

Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis.

Lindner DJ, Wu Y, Haney R, Jacobs BS, Fruehauf JP, Tuthill R, Borden EC.

Matrix Biol. 2013 Mar 11;32(2):123-32. doi: 10.1016/j.matbio.2012.11.010. Epub 2012 Nov 30.

6.
7.

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE 3rd, O'Day SJ.

J Clin Oncol. 2012 Jan 1;30(1):34-41. doi: 10.1200/JCO.2011.34.6270. Epub 2011 Nov 28.

8.

Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma.

Eroglu Z, Kong KM, Jakowatz JG, Samlowski W, Fruehauf JP.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1081-7. doi: 10.1007/s00280-011-1703-z. Epub 2011 Jul 19.

9.

Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors.

Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, Bair AH, Ricart AD, Olszanski AJ, Letrent KJ, Kim S, Rixe O.

Clin Cancer Res. 2011 Jun 1;17(11):3841-9. doi: 10.1158/1078-0432.CCR-10-2806. Epub 2011 Apr 29.

10.

Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture.

Trapp V, Parmakhtiar B, Papazian V, Willmott L, Fruehauf JP.

Angiogenesis. 2010 Dec;13(4):305-15. doi: 10.1007/s10456-010-9187-8. Epub 2010 Oct 7.

11.

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.

Han ES, Burger RA, Darcy KM, Sill MW, Randall LM, Chase D, Parmakhtiar B, Monk BJ, Greer BE, Connelly P, Degeest K, Fruehauf JP.

Gynecol Oncol. 2010 Dec;119(3):484-90. doi: 10.1016/j.ygyno.2010.08.016. Epub 2010 Sep 25.

12.

Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study.

Randall LM, Monk BJ, Moon J, Parker R, Al-Ghazi M, Wilczynski S, Fruehauf JP, Markman M, Burger RA.

Gynecol Oncol. 2010 Dec;119(3):417-21. doi: 10.1016/j.ygyno.2010.08.010. Epub 2010 Sep 16.

13.

Targeted therapy in ovarian cancer.

Willmott LJ, Fruehauf JP.

J Oncol. 2010;2010:740472. doi: 10.1155/2010/740472. Epub 2010 Jan 14.

14.

Redox-related antimelanoma activity of ATN-224.

Trapp V, Lee K, DoƱate F, Mazar AP, Fruehauf JP.

Melanoma Res. 2009 Dec;19(6):350-60. doi: 10.1097/CMR.0b013e32832c6324.

PMID:
22760066
15.

Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study.

Liao SY, Darcy KM, Randall LM, Tian C, Monk BJ, Burger RA, Fruehauf JP, Peters WA, Stock RJ, Stanbridge EJ.

Gynecol Oncol. 2010 Mar;116(3):452-8. doi: 10.1016/j.ygyno.2009.10.062. Epub 2009 Nov 13.

16.

Prediction of drug response in breast cancer using integrative experimental/computational modeling.

Frieboes HB, Edgerton ME, Fruehauf JP, Rose FR, Worrall LK, Gatenby RA, Ferrari M, Cristini V.

Cancer Res. 2009 May 15;69(10):4484-92. doi: 10.1158/0008-5472.CAN-08-3740. Epub 2009 Apr 14.

17.

Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.

Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peters WA, Stock RJ, Fruehauf JP.

Gynecol Oncol. 2009 Mar;112(3):583-9. doi: 10.1016/j.ygyno.2008.11.013. Epub 2008 Dec 24.

18.

Reactive oxygen species: an Achilles' heel of melanoma?

Fruehauf JP, Trapp V.

Expert Rev Anticancer Ther. 2008 Nov;8(11):1751-7. doi: 10.1586/14737140.8.11.1751. Review.

PMID:
18983235
19.

The effect of bevacizumab (Avastin) on neuroimaging of brain metastases.

Mathews MS, Linskey ME, Hasso AN, Fruehauf JP.

Surg Neurol. 2008 Dec;70(6):649-52; discussion 653. doi: 10.1016/j.surneu.2007.06.029. Epub 2008 Feb 8.

PMID:
18261776
20.

Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression.

Einspahr JG, Thomas TL, Saboda K, Nickolof BJ, Warneke J, Curiel-Lewandrowski C, Ranger-Moore J, Duckett L, Bangert J, Fruehauf JP, Alberts DS.

Cancer. 2007 Dec 1;110(11):2519-27.

21.

Reactive oxygen species: a breath of life or death?

Fruehauf JP, Meyskens FL Jr.

Clin Cancer Res. 2007 Feb 1;13(3):789-94. Review.

22.

Mathematical modeling of cancer progression and response to chemotherapy.

Sanga S, Sinek JP, Frieboes HB, Ferrari M, Fruehauf JP, Cristini V.

Expert Rev Anticancer Ther. 2006 Oct;6(10):1361-76. Review.

PMID:
17069522
23.

Pharmacogenomics of colorectal cancer prevention and treatment.

Nguyen H, Tran A, Lipkin S, Fruehauf JP.

Cancer Invest. 2006 Oct;24(6):630-9. Review.

PMID:
16982469
24.

A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.

Prabhu S, Saadat D, Zhang M, Halbur L, Fruehauf JP, Ong ST.

Oncogene. 2007 Feb 22;26(8):1188-200. Epub 2006 Aug 28.

25.

In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.

Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, Huang W, Parker R.

Clin Cancer Res. 2006 Aug 1;12(15):4523-32.

26.

A tale of two growth factors.

Fruehauf JP, Kong KM, Wong SF, Chan HO.

Pharmacotherapy. 2006 Mar;26(3):443-4; discussion 444. No abstract available.

PMID:
16503728
27.

Gene expression profiling of in vitro radiation resistance in cervical carcinoma: a feasibility study.

Tewari D, Monk BJ, Al-Ghazi MS, Parker R, Heck JD, Burger RA, Fruehauf JP.

Gynecol Oncol. 2005 Oct;99(1):84-91.

PMID:
16109440
28.

Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma.

Tewari KS, Mehta RS, Burger RA, Yu IR, Kyshtoobayeva AS, Monk BJ, Manetta A, Berman ML, Disaia PJ, Fruehauf JP.

Gynecol Oncol. 2005 Sep;98(3):360-8.

29.

Docetaxel and vinorelbine plus GM-CSF in malignant melanoma.

Fruehauf JP, Kong KM, Jakowatz JG.

Oncology (Williston Park). 2005 Apr;19(4 Suppl 2):19-22.

30.

In vitro drug resistance versus chemosensitivity: two sides of different coins.

Fruehauf JP, Alberts DS.

J Clin Oncol. 2005 May 20;23(15):3641-3; author reply 3646-8. Review. No abstract available.

PMID:
15908686
31.

The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer.

Goodheart MJ, Ritchie JM, Rose SL, Fruehauf JP, De Young BR, Buller RE.

Clin Cancer Res. 2005 May 15;11(10):3733-42.

32.

Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator.

Fabian CJ, Kimler BF, Anderson J, Tawfik OW, Mayo MS, Burak WE Jr, O'Shaughnessy JA, Albain KS, Hyams DM, Budd GT, Ganz PA, Sauter ER, Beenken SW, Grizzle WE, Fruehauf JP, Arneson DW, Bacus JW, Lagios MD, Johnson KA, Browne D.

Clin Cancer Res. 2004 Aug 15;10(16):5403-17.

33.

A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma.

Parker RJ, Fruehauf JP, Mehta R, Filka E, Cloughesy T.

J Neurooncol. 2004 Feb;66(3):365-75.

PMID:
15015670
34.

In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.

Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP.

Gynecol Oncol. 2004 Jan;92(1):160-6.

PMID:
14751152
35.

Endometriosis-associated ovarian carcinoma: differential expression of vascular endothelial growth factor and estrogen/progesterone receptors.

Del Carmen MG, Smith Sehdev AE, Fader AN, Zahurak ML, Richardson M, Fruehauf JP, Montz FJ, Bristow RE.

Cancer. 2003 Oct 15;98(8):1658-63.

36.

Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer.

Su MY, Cheung YC, Fruehauf JP, Yu H, Nalcioglu O, Mechetner E, Kyshtoobayeva A, Chen SC, Hsueh S, McLaren CE, Wan YL.

J Magn Reson Imaging. 2003 Oct;18(4):467-77.

PMID:
14508784
37.

Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine.

Sommers KR, Kong KM, Bui DT, Fruehauf JP, Holcombe RF.

Anticancer Drugs. 2003 Sep;14(8):659-62.

PMID:
14501389
38.

Analysis of P-glycoprotein-mediated membrane transport in human peripheral blood lymphocytes using the UIC2 shift assay.

Park SW, Lomri N, Simeoni LA, Fruehauf JP, Mechetner E.

Cytometry A. 2003 Jun;53(2):67-78.

39.

Measurement of volumetric and vascular changes with dynamic contrast enhanced MRI for cancer therapy monitoring.

Su MY, Yu H, Chiou JY, Wang J, Nalcioglu O, Fruehauf JP, Mehta RS, Baick CH.

Technol Cancer Res Treat. 2002 Dec;1(6):479-88.

PMID:
12625775
40.

Assay-assisted treatment selection for women with breast or ovarian cancer.

Fruehauf JP, Alberts DS.

Recent Results Cancer Res. 2003;161:126-45. Review.

PMID:
12528805
41.

Development of an in vitro chemo-radiation response assay for cervical carcinoma.

Monk BJ, Burger RA, Parker R, Radany EH, Redpath L, Fruehauf JP.

Gynecol Oncol. 2002 Nov;87(2):193-9.

PMID:
12477451
42.

Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.

Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Fruehauf JP.

Gynecol Oncol. 2002 Oct;87(1):8-16.

PMID:
12468336
43.

In vitro assay-assisted treatment selection for women with breast or ovarian cancer.

Fruehauf JP.

Endocr Relat Cancer. 2002 Sep;9(3):171-82. Review.

PMID:
12237245
44.

Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens.

Haroun RI, Clatterbuck RE, Gibbons MC, Burger PC, Parker R, Fruehauf JP, Brem H.

J Neurooncol. 2002 Jun;58(2):115-23.

PMID:
12164682
45.

Factors associated with success of the extreme drug resistance assay in primary breast cancer specimens.

Ellis RJ, Fabian CJ, Kimler BF, Tawfik O, Mayo MS, Decelis CR, Jewell WR, Connor C, Modrell C, Praeger M, McGinness M, Mehta R, Fruehauf JP.

Breast Cancer Res Treat. 2002 Jan;71(2):95-102.

PMID:
11881914
46.

The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature.

Reavey-Cantwell JF, Haroun RI, Zahurak M, Clatterbuck RE, Parker RJ, Mehta R, Fruehauf JP, Brem H.

J Neurooncol. 2001 Dec;55(3):195-204. Review.

PMID:
11859975
47.

Breast cancer survival and in vitro tumor response in the extreme drug resistance assay.

Mehta RS, Bornstein R, Yu IR, Parker RJ, McLaren CE, Nguyen KP, Li KT, Fruehauf JP.

Breast Cancer Res Treat. 2001 Apr;66(3):225-37.

PMID:
11510694
48.

Redox regulation in human melanocytes and melanoma.

Meyskens FL Jr, Farmer P, Fruehauf JP.

Pigment Cell Res. 2001 Jun;14(3):148-54. Review.

PMID:
11434561
49.

Independent association of angiogenesis index with outcome in prostate cancer.

Mehta R, Kyshtoobayeva A, Kurosaki T, Small EJ, Kim H, Stroup R, McLaren CE, Li KT, Fruehauf JP.

Clin Cancer Res. 2001 Jan;7(1):81-8.

50.

Biomarker conservation in primary and metastatic epithelial ovarian cancer.

Tewari KS, Kyshtoobayeva AS, Mehta RS, Yu IR, Burger RA, DiSaia PJ, Fruehauf JP.

Gynecol Oncol. 2000 Aug;78(2):130-6.

Supplemental Content

Loading ...
Support Center